Literature DB >> 1646107

Hormonal regulation of potassium shifts during graded exhausting exercise.

F J Laso1, J M González-Buitrago, C Martín Ruiz, S de Castro.   

Abstract

Serum potassium, aldosterone and insulin, and plasma adrenaline, noradrenaline and cyclic adenosine 3':5'-monophosphate (cAMP) concentrations were measured during graded exhausting exercise and during the following 30 min recovery period in six untrained young men. During exercise there was an increase in concentration of serum potassium (4.74 mmol.l-1, SEM 0.12 at the end of exercise vs 3.80 mmol.l-1, SEM 0.05 basal, P less than 0.001), plasma adrenaline (2.14 nmol.l-1, SEM 0.05 at the end of exercise vs 0.30 nmol.l-1, SEM 0.02 basal, P less than 0.001), plasma noradrenaline (1.10 nmol.l-1, SEM 0.64 at the end of exercise vs 1.50 nmol.l-1, SEM 0.05 basal, P less than 0.001), serum aldosterone (0.92 nmol.l-1, SEM 0.14 at the end of exercise vs 0.36 nmol.l-1, SEM 0.05 basal, P less than 0.01), and plasma cAMP (35.4 nmol.l-1, SEM 2.3 at the end of exercise vs 21.4 nmol.l-1, SEM 4.5 basal, P less than 0.05). While concentrations of serum potassium, plasma adrenaline and cAMP returned to their basal levels immediately after exercise, those of plasma noradrenaline and serum aldosterone remained elevated 30 min later (1.90 nmol.l-1, SEM 0.01, P less than 0.01; and 0.85 nmol.l-1, SEM 0.12, P less than 0.01, respectively). Serum insulin concentration did not change during exercise (6.47 mlU.l-1, SEM 0.58 at the end of exercise vs 5.47 mlU.l-1, SEM 0.41 basal, NS) but increased significantly (P less than 0.02) at the end of the recovery period (7.12 mlU.l-1, SEM 0.65).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1646107     DOI: 10.1007/bf00571555

Source DB:  PubMed          Journal:  Eur J Appl Physiol Occup Physiol        ISSN: 0301-5548


  26 in total

1.  Kalemotropic effect of epinephrine: analysis with adrenergic agonists and antagonists.

Authors:  E P Todd; R L Vick
Journal:  Am J Physiol       Date:  1971-06

2.  Epinephrine-induced hypokalemia: relation to liver and skeletal muscle.

Authors:  R L Vick; E P Todd; D W Luedke
Journal:  J Pharmacol Exp Ther       Date:  1972-04       Impact factor: 4.030

3.  Functional impairment in chronic renal disease. 3. Studies of potassium excretion.

Authors:  H C Gonick; C R Kleeman; M E Rubini; M H Maxwell
Journal:  Am J Med Sci       Date:  1971-05       Impact factor: 2.378

4.  Adrenaline and potassium: everything in flux.

Authors: 
Journal:  Lancet       Date:  1983-12-17       Impact factor: 79.321

5.  Beta adrenergic control of extrarenal potassium disposal. A beta-2 mediated phenomenon.

Authors:  M J Bia; D Lu; K Tyler; R A De Fronzo
Journal:  Nephron       Date:  1986       Impact factor: 2.847

6.  Impairment of extrarenal potassium disposal by alpha-adrenergic stimulation.

Authors:  M E Williams; R M Rosa; P Silva; R S Brown; F H Epstein
Journal:  N Engl J Med       Date:  1984-07-19       Impact factor: 91.245

Review 7.  Sudden cardiac death in sport.

Authors:  R J Northcote; D Ballantyne
Journal:  Br Med J (Clin Res Ed)       Date:  1983-11-05

8.  Influence of metabolic control of insulin-dependent diabetes on plasma nucleotide levels (cAMP, cGMP) during bicycle exercise.

Authors:  R Kuzmits; G Schernthaner
Journal:  Diabet Med       Date:  1986 Sep-Oct       Impact factor: 4.359

9.  Comparison of the effectiveness of various routes of insulin injection: insulin levels and glucose response in normal subjects.

Authors:  S M Guerra; A E Kitabchi
Journal:  J Clin Endocrinol Metab       Date:  1976-05       Impact factor: 5.958

10.  The effect of exercise on platelet beta-adrenoceptor function and platelet aggregation in healthy human volunteers.

Authors:  K Winther; J Trap-Jensen
Journal:  Clin Physiol       Date:  1988-04
View more
  1 in total

1.  Effect of beta 2-adrenoceptor agonists on plasma potassium and cardiopulmonary responses on exercise in patients with chronic obstructive pulmonary disease.

Authors:  C T Yang; H C Lin; M C Lin; C H Wang; C H Lee; H P Kuo
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.